New Malaria Drug Candidate Passes First-in-Human Test

NEW YORK (Reuters Health) – ZY19489, a novel triaminopyrimidine antimalarial compound, has successfully passed a first-in-human clinical trial, demonstrating promising safety, pharmacokinetics and antimalarial activity, according to a new report. Conducted in 48 healthy adult volunteers in Australia, the study showed ZY-19489 was well tolerated up to the maximum dose tested of 1,500 mg, Dr. Bridget Barber with QIMR Berghofer […]
Continue reading »